Abstract
Bilberry extracts containing anthocyanins have become rather popular within the last 2 years among patients with age-related macular degeneration (AMD) in Switzerland as a medication for primary or secondary prophylaxis. So far human study results concerning safety and efficacy in AMD patients are not available. The present state of the scientific literature concerning the use of anthocyanins with relation to AMD will be analysed in this review.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
